A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial ...

A five-year-old boy who received the world's most expensive drug as a baby has made "incredible progress" and can walk ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...

A 10-month-old baby who sparked nationwide headlines after receiving a first-of-its kind gene-editing treatment was released from the hospital this week.

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...

Medscape Medical News talked with researcher Stacie Dusetzina about the prospects for a single-payer program to help with the ...

Live Science's health channel editor makes predictions about the medical breakthroughs and public health shifts to come in ...